Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Breast Cancer Res Treat. 2012 Oct 31;136(3):837–845. doi: 10.1007/s10549-012-2308-x

Table 3.

Odds ratio (OR) and 95% confidence intervals (CI) for the association of postmenopausal breast cancer with plasma MMP levels by subgroup of participant characteristics a

Variables Numbers MMP-1 MMP-2 MMP-3 MMP-7





Cases Controls OR (95% CI) Pint d OR (95% CI) Pint d OR (95% CI) Pint d OR (95% CI) Pint d
Age, y b 0.85 0.69 0.62 0.22
    <65 282 277 1.17 (0.79–1.72) 0.86 (0.57–1.30) 0.83 (0.57–1.22) 1.30 (0.88–1.93)
    ≥65 431 436 1.01 (0.76–1.34) 0.93 (0.69–1.25) 1.00 (0.75–1.34) 0.95 (0.71–1.28)
Ethnicity b 0.98 0.96 0.33 0.81
    White 151 151 1.29 (0.78–2.10) 1.11 (0.66–1.90) 0.88 (0.55–1.42) 0.91 (0.54–1.52)
    African-American 107 107 0.92 (0.52–1.64) 0.57 (0.28–1.18) 1.58 (0.78–3.18) 1.25 (0.63–2.47)
    Native Hawaiian 68 68 0.96 (0.44–2.07) 1.16 (0.57–2.34) 0.93 (0.50–1.75) 0.96 (0.49–1.87)
    Japanese-American 254 254 0.99 (0.68–1.44) 0.94 (0.63–1.41) 0.89 (0.60–1.30) 1.18 (0.79–1.77)
    Latino 133 133 1.43 (0.81–2.52) 0.88 (0.48–1.60) 0.78 (0.44–1.39) 1.06 (0.61–1.86)
Body mass index c 0.03 0.71 0.68 0.64
    <25.0 320 382 0.91 (0.66–1.24) 1.00 (0.72–1.39) 0.96 (0.71–1.32) 1.01 (0.73–1.40)
    25.0–29.9 250 199 1.08 (0.74–1.60) 0.66 (0.43–1.02) 0.76 (0.50–1.15) 0.99 (0.67–1.47)
    ≥30.0 129 122 1.77 (1.02–3.06) 1.47 (0.85–2.57) 1.16 (0.67–2.01) 1.17 (0.68–2.02)
Hormone replacement therapy use b 0.04 0.62 0.64 0.96
    No 472 472 0.92 (0.70–1.20) 0.90 (0.67–1.21) 1.00 (0.76–1.33) 1.10 (0.82–1.47)
    Yes 241 241 1.73 (1.16–2.59) 1.01 (0.69–1.50) 0.91 (0.63–1.32) 0.98 (0.67–1.42)

Abbreviation: MMP, matrix metalloproteinase; Pint, P Value for interaction.

a

Odds ratios and 95% confidence intervals were based on a change in two standard deviation of the log-transformed plasma MMPs (pg/mL).

b

Modeled through conditional logistic regression after adjustment for body mass index, number of live births, and family history of breast cancer.

c

Modeled through unconditional logistic regression model after adjustment for body mass index, number of live births, family history of breast cancer, study area, ethnicity, birth year, date of blood draw, fasting time, and use of hormone replacement therapy.

d

Tests for interaction based on the Wald statistic for cross-product terms between the corresponding variable and the log-transformed plasma MMP level.